HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Subscribe To Our Newsletter & Stay Updated